Digoxin Toxicity

Quick Answer

One-liner: Digoxin toxicity is a potentially life-threatening condition caused by Na+/K+ ATPase inhibition, presenting with cardiac arrhythmias, hyperkalaemia, and non-specific symptoms; treatment includes cardiac monitoring, electrolyte correction, and digoxin-specific Fab antibodies for severe cases.

Digoxin toxicity occurs when serum levels exceed the therapeutic window (0.5-2.0 ng/mL), inhibiting myocardial Na+/K+ ATPase pumps and increasing intracellular calcium. This causes increased automaticity, decreased conduction velocity, and enhanced vagal tone. Acute overdose presents with gastrointestinal symptoms, while chronic toxicity manifests with non-specific constitutional symptoms. Life-threatening cardiac arrhythmias include ventricular tachycardia, ventricular fibrillation, and high-grade AV block. Hyperkalaemia is a hallmark finding and prognostic marker. Digoxin-specific Fab antibody fragments (DigiFab) rapidly bind free digoxin, reversing toxicity. Mortality is 5-10% with appropriate treatment, up to 50% without Fab therapy in severe cases.

---

ACEM Exam Focus

Primary Exam Relevance

Anatomy:

• Cardiac conduction system (SA node, AV node, His-Purkinje system)
• Myocardial cell membrane structure and ion channels

Physiology:

• Na+/K+ ATPase pump function and electrochemical gradient maintenance
• Cardiac action potential phases and ion fluxes
• Autonomic nervous system regulation of heart rate and conduction
• Calcium handling in myocardial cells

Pharmacology:

• Cardiac glycosides: mechanism of action, therapeutic effects, toxic effects
• Fab antibody fragments: pharmacokinetics, dosing, elimination
• Drug interactions: P-glycoprotein inhibitors, electrolyte interactions
• Antiarrhythmic drugs contraindicated in digoxin toxicity (calcium, beta-blockers)

Fellowship Exam Relevance

Written:

• Recognising digoxin toxicity on ECG (sagging ST depression, bidirectional VT, AV block)
• Indications for Fab antibody therapy
• Acute vs chronic toxicity management differences
• BRASH syndrome (Bradycardia, Renal failure, AV nodal blockade, Shock, Hyperkalaemia)

OSCE:

• Resuscitation station: Managing unstable patient with digoxin toxicity
• Communication station: Breaking bad news about digoxin overdose
• History/examination: Identifying digoxin toxicity clues

Key domains tested: Medical Expert (diagnosis and management), Communicator (drug safety counselling), Professional (recognising iatrogenic harm)

---

Key Points

---

Epidemiology

Australian/NZ Specific

• Declining incidence: From 12.5/100,000 in 2005 to 4.2/100,000 in 2020 due to reduced digoxin prescribing for atrial fibrillation [9]
• NSW data: 150-200 hospital admissions annually for digoxin toxicity [10]
• Māori population: 30% lower digoxin prescription rates, similar toxicity rates when prescribed [11]
• Indigenous Australians: 2-3x higher risk of chronic toxicity due to higher prevalence of CKD and reduced access to therapeutic drug monitoring [12]
• Rural/remote: 40% longer time to Fab administration (median 6.5 hours vs 4.6 hours metropolitan) [13]

---

Pathophysiology

Mechanism of Action and Toxicity

Normal Physiology:

• Na+/K+ ATPase pump transports 3 Na+ out, 2 K+ in against concentration gradient
• Maintains resting membrane potential (-85 to -90 mV)
• Uses ATP to drive active transport

Digoxin Inhibition:

• Binds extracellular alpha-subunit of Na+/K+ ATPase
• Competitive inhibition at the K+ binding site
• Reversible, concentration-dependent binding

Cellular Consequences:

Na+/K+ ATPase inhibition → ↑ intracellular Na+
→ ↓ Na+/Ca2+ exchanger (NCX) function → ↑ intracellular Ca2+
→ Enhanced myocardial contractility (positive inotropy)
→ Increased automaticity (enhanced phase 4 depolarisation)
→ Decreased conduction velocity (decreased action potential upstroke)

Neurohormonal Effects:

• Direct vagal nucleus stimulation → increased acetylcholine release
• Enhanced baroreceptor sensitivity
• Decreased sympathetic outflow

Electrolyte Effects:

• Inhibits Na+/K+ ATPase in renal tubules → ↑ renal K+ excretion
• Paradoxically causes hyperkalaemia in toxicity due to massive cellular Na+/K+ pump failure

Pathological Progression

Acute Overdose (hours):
GI symptoms (nausea, vomiting) → Autonomic effects (bradycardia, AV block)
→ Cardiac arrhythmias (PVCs, atrial tachycardia with block)
→ Severe toxicity (VT/VF, asystole)

Chronic Toxicity (weeks-months):
Subtle symptoms (fatigue, anorexia, confusion) → Electrolyte imbalance
→ Progressive cardiac conduction abnormalities → Decompensation

BRASH Syndrome (vicious cycle):
Bradycardia → Renal hypoperfusion → AKI → Digoxin accumulation
→ Further bradycardia → Worsening renal failure

Toxicity Determinants

Why It Matters Clinically

Understanding Na+/K+ ATPase inhibition explains:

1. Why hyperkalaemia occurs: Massive pump failure releases intracellular K+
2. Why low K+ precipitates toxicity: Competition at binding site, less pump inhibition needed
3. Why calcium is dangerous: "Stone heart"

• calcium + digoxin causes sustained myocardial contraction and systolic arrest

4. Why Fab works: Antibody binds digoxin with higher affinity than ATPase, removing it from circulation
5. Why timing matters: Chronic toxicity presents differently (lower serum levels but higher tissue stores)

---

Clinical Approach

Recognition

High-Risk Scenarios:

• Patient on digoxin with renal impairment, especially CKD stages 3-5
• Recent dose escalation or drug interaction started
• Intentional overdose with known access to digoxin
• Unexplained bradycardia or AV block in elderly patient

Key Triggers for Digoxin Level Check:

• Heart rate below 60/min in patient on digoxin
• New visual disturbances (yellow halos - xanthopsia)
• Gastrointestinal symptoms (nausea, vomiting, anorexia)
• Unexplained confusion or fatigue in elderly patient
• Electrolyte disturbances (hypokalaemia, hypomagnesaemia, hypercalcaemia)
• Adding interacting medication (amiodarone, verapamil, macrolides)

Initial Assessment

Primary Survey (if unstable)

• A: Airway protection if decreased consciousness or vomiting
• B: Respiratory support if pulmonary oedema or arrhythmia causes compromise
• C: Cardiac monitoring, IV access, bloods including digoxin level
• D: GCS assessment, neurological observation
• E: ECG, check for medication bottles, check for recent drug prescription changes

History

Key Questions

Red Flag Symptoms

Examination

General Inspection

• Vital signs: Bradycardia (most common), hypotension (late finding)
• Skin: Cool, clammy if cardiac compromise
• Neurological: Confusion, agitation (elderly), hallucinations (severe)

Specific Findings

---

Investigations

Immediate (Resus Bay)

Standard ED Workup

Advanced/Specialist

Point-of-Care Ultrasound

Applications in Digoxin Toxicity:

• Cardiac: Assess global systolic function, wall motion abnormalities, exclude other causes of cardiac dysfunction
• IVC assessment: Volume status guide for fluid resuscitation (caution: toxicity can cause cardiogenic shock)
• Lung ultrasound: B-lines to detect pulmonary oedema
• Focused cardiac ultrasound: Identify severe LV dysfunction, wall motion abnormalities

Limitations: POCUS cannot diagnose digoxin toxicity but supports clinical assessment and excludes differentials.

---

Management

Immediate Management (First 10 minutes)

1. ABCDE assessment, cardiac monitoring, 2 large-bore IV access
2. 12-lead ECG immediately, continuous rhythm monitoring
3. Serum digoxin level, electrolytes (K+, Mg2+, Ca2+), creatinine, toxicology screen
4. Assess for Fab antibody indication (see criteria below)
5. If unstable: Atropine 0.5-1 mg IV (max 3 mg) for bradycardia
6. Consider temporary pacing if symptomatic high-grade AV block
7. Activated charcoal 50 g PO (if within 2 hours of acute ingestion and airway protected)
8. Admit to monitored bed (all confirmed or suspected cases)

Resuscitation

Airway

• Protect airway if decreased GCS below 13 (Glasgow Coma Scale)
• Rapid sequence intubation if respiratory compromise from pulmonary oedema or arrhythmia
• Avoid succinylcholine in hyperkalaemia (risk of further K+ release)

Breathing

• Supplemental oxygen if SpO2 below 94%
• Non-invasive ventilation for pulmonary oedema (CPAP first line)
• Intubation and mechanical ventilation if NIV fails or refractory hypoxia
• Lung-protective ventilation if acute lung injury

Circulation

Haemodynamic Targets:

• MAP above 65 mmHg
• Heart rate above 60/min (unless permanent AF)
• Urine output above 0.5 mL/kg/hr

Interventions:

• Crystalloid bolus 500-1000 mL if hypovolaemic (caution: may worsen pulmonary oedema)
• Atropine 0.5-1 mg IV (repeat to 3 mg max) for symptomatic bradycardia
• Temporary transvenous pacing for high-grade AV block or symptomatic bradycardia refractory to atropone
• Norepinephrine infusion if vasodilatory shock (avoid dopamine, can cause arrhythmias)
• Dobutamine or milrinone for cardiogenic shock (inotropes, digoxin already provides inotropy)

Contraindicated in Digoxin Toxicity:

• Calcium gluconate/chloride IV: Risk of "stone heart" (sustained myocardial contraction)
• Beta-blockers: Worsen AV block, further decrease heart rate
• Calcium channel blockers: Worsen AV block, negative inotropy
• Class I antiarrhythmics (flecainide, propafenone): Proarrhythmic, depress conduction further
• Electrical cardioversion: Risk of precipitating VF (use lowest energy needed, 10-20 J if essential)

Medications

Acute Overdose Management

Chronic Toxicity Management

Fab Antibody (DigiFab) Dosing

Acute Overdose:

Body load (mg) = Ingested amount (mg) × 0.8 (oral bioavailability)
Number of vials = Body load (mg) / 0.5 (binding capacity per vial)

Example: 10 mg acute ingestion
Body load = 10 × 0.8 = 8 mg
Vials needed = 8 / 0.5 = 16 vials

Chronic Toxicity:

• Start with 1-2 vials IV over 30 minutes
• Additional vials may be needed based on clinical response
• Smaller doses than acute (tissue saturation, lower serum levels)

Special Situations:

• Unknown dose: Give 6-10 vials for suspected acute overdose
• Chronic toxicity with unknown level: 1-2 vials, titrate
• Paediatric: Use same calculation based on estimated ingestion
• Pregnancy: Fab crosses placenta, benefits usually outweigh risks in life-threatening toxicity

Post-Fab Monitoring:

• Serum digoxin level (total and free): 2-4 hours post-administration
• Repeat digoxin level in 24-48 hours (rebound toxicity possible)
• Cardiac monitoring minimum 24 hours, longer if renal impairment
• Monitor potassium (may fall rapidly as toxicity reverses)

Paediatric Dosing

Ongoing Management

Admission Criteria:

• All confirmed digoxin toxicity
• Symptomatic bradycardia or arrhythmia
• Serum digoxin above 2.0 ng/mL
• Hyperkalaemia above 5.5 mmol/L
• Renal impairment (eGFR below 60 mL/min)
• Significant drug interactions

ICU/HDU Criteria:

• Life-threatening arrhythmias (VT/VF, asystole)
• High-grade AV block requiring pacing
• Cardiogenic shock
• Severe hyperkalaemia (above 6.5 mmol/L)
• Received Fab antibody therapy
• Age above 75 with significant comorbidities

Inpatient Monitoring:

• Continuous cardiac monitoring minimum 24 hours
• Hourly vital signs for 6 hours, then 4-hourly
• Serum digoxin level at presentation, then 6-hourly until stable
• Serum potassium 6-hourly until below 5.0 mmol/L
• Creatinine and electrolytes daily
• Repeat ECG at 6, 12, 24 hours post-Fab

Rebound Toxicity:

• Occurs 24-48 hours post-Fab due to release from tissue stores
• Monitor for recurrent symptoms or arrhythmias
• Repeat digoxin level if clinical deterioration
• Additional Fab may be required

Definitive Care

Nephrology Consultation:

• If eGFR below 30 mL/min
• If requiring dialysis for refractory hyperkalaemia (rarely needed, Fab usually sufficient)

Cardiology Consultation:

• If high-grade AV block
• If ventricular arrhythmias
• If temporary or permanent pacing required
• For underlying cardiac disease management

Toxicology Consultation:

• For complex overdoses
• For Fab dosing confirmation
• For management of multiple drug ingestions

Discharge Planning:

• Review indication for digoxin (consider alternative)
• Dose adjustment based on renal function
• Patient education on toxicity symptoms
• Medication review to avoid interactions
• Arrange GP follow-up in 5-7 days with repeat digoxin level

---

Disposition

Admission Criteria

All confirmed digoxin toxicity requires admission to:

• ICU/HDU: Severe toxicity (see above)
• Monitored ward: Mild-moderate toxicity

Specific indications:

• Symptomatic bradycardia (HR below 50 with hypotension or syncope)
• Any ventricular arrhythmia
• 2nd or 3rd degree AV block
• Serum digoxin above 4.0 ng/mL (acute) or above 2.0 ng/mL (chronic)
• Hyperkalaemia above 5.5 mmol/L
• Received Fab antibody therapy
• Renal impairment (eGFR below 60 mL/min)

ICU/HDU Criteria

• Life-threatening arrhythmias (VT/VF, asystole)
• High-grade AV block (Mobitz II, 3rd degree)
• Cardiogenic shock requiring vasopressors
• Severe hyperkalaemia (above 6.5 mmol/L)
• Received Fab antibody with ongoing instability
• Age above 75 with multiple comorbidities

Discharge Criteria

Safe Discharge Possible:

• Asymptomatic
• Serum digoxin below 2.0 ng/mL and stable or trending down
• Normal ECG (no arrhythmias, PR interval below 0.20 sec)
• Serum potassium below 5.0 mmol/L
• Adequate renal function (eGFR above 60 mL/min)
• No Fab antibody required

Red Flags to Return:

• Bradycardia (HR below 50)
• Dizziness, presyncope, syncope
• Chest pain, palpitations
• Visual disturbances
• Recurrent nausea or vomiting
• New confusion or agitation

Follow-up

Immediate (within 7 days):

• GP review with repeat digoxin level
• Review renal function (creatinine, eGFR)
• Medication reconciliation

Long-term:

• Consider alternative anti-arrhythmic or rate control agent
• If digoxin continued:
  • Reduced dose (125 mcg daily or less)
  • Regular monitoring (every 3-6 months)
  • Renal function monitoring
  • Medication review for interactions

GP Letter Requirements:

• Presenting symptoms and signs
• Serum digoxin levels (admission and discharge)
• Electrolyte abnormalities and correction
• Fab antibody administration (if given)
• Discharge medications and dosing
• Follow-up recommendations
• Red flags for return to ED

---

Special Populations

Paediatric Considerations

Epidemiology:

• Accidental ingestion uncommon (small number of tablets needed for toxicity)
• Intentional overdose in adolescents (similar to adults)
• Lower doses cause toxicity (4 mg potentially fatal)

Dose Calculation:

• Maintenance dose: 10-15 mcg/kg/day divided BID
• Loading dose (if required): 20-30 mcg/kg divided over 24 hours
• 50% dose reduction if eGFR below 50 mL/min/1.73m²

Management Differences:

• Fab dose calculation same as adults based on estimated ingestion
• Smaller body load requires fewer vials
• Higher mortality in massive overdose due to cardiovascular collapse

Monitoring:

• Therapeutic level: 0.8-2.0 ng/mL (children tolerate higher levels)
• More frequent monitoring in chronic therapy

Pregnancy

FDA Classification: Category C (risk cannot be ruled out)

Maternal Risks:

• Same as non-pregnant: arrhythmias, hyperkalaemia
• Physiological changes increase toxicity risk:
  • Increased plasma volume (early) then decreased (late)
  • Decreased GFR in first trimester, increased in second/third
  • Hormonal effects on conduction system

Fetal Risks:

• Digoxin crosses placenta (fetal:maternal ratio 0.6-1.0)
• Potential for fetal bradycardia
• Teratogenic: Not clearly established, avoid first trimester if possible

Management:

• Consider alternative rate control (beta-blockers, CCBs)
• If digoxin essential: Use lowest effective dose (62.5-125 mcg daily)
• Monitor fetal heart rate with maternal toxicity
• Fab antibody crosses placenta: Benefits outweigh risks in life-threatening maternal toxicity
• Obstetric consult if moderate-severe toxicity

Breastfeeding:

• Digoxin excreted in breast milk (infant dose below 1% of maternal dose)
• Generally considered compatible with breastfeeding
• Monitor infant for signs of toxicity if breastfed by mother on digoxin

Elderly

Increased Risk Factors:

• Age-related renal function decline (GFR decreases 1 mL/min/year after age 40)
• Reduced volume of distribution
• Polypharmacy (increased drug interactions)
• Altered protein binding
• Comorbidities (CKD, heart failure, AF)

Dose Adjustment:

• Start 62.5 mcg daily (or 125 mcg every other day)
• Maximum dose: 125 mcg daily in most elderly
• Contraindicated if eGFR below 30 mL/min

Clinical Presentation:

• Non-specific symptoms (fatigue, anorexia, confusion) common
• Often misdiagnosed as "just getting old"
• Delirium may be only manifestation

Monitoring:

• Therapeutic level: 0.5-1.5 ng/mL (lower target)
• Monitor weekly for first month, then monthly
• Renal function every 3 months

Drug Interaction Vigilance:

• Amiodarone: Reduce digoxin dose by 50% when added
• Verapamil, diltiazem: Reduce digoxin dose by 30-50%
• Macrolide antibiotics: Hold digoxin or reduce dose by 50%
• Loop diuretics: Monitor K+ and Mg2+, replace aggressively

Indigenous Health

Important Note: Aboriginal, Torres Strait Islander, and Māori considerations:

Health Disparities:

• Aboriginal and Torres Strait Islander peoples: 2-3x higher incidence of CKD stages 3-5 (major digoxin toxicity risk factor) [14]
• Māori: Higher prevalence of rheumatic heart disease and atrial fibrillation, increased digoxin use [15]
• Reduced access to therapeutic drug monitoring in rural/remote communities [16]
• Later presentation to healthcare (median 48 hours after symptom onset vs 18 hours urban) [17]

Cultural Safety:

• Use interpreter services if English is second language (ATSI 20% preferential use of Indigenous languages in remote areas) [18]
• Explain "digoxin" using culturally appropriate terminology ("heart strength medicine")
• Involve Aboriginal Health Worker or Māori cultural liaison in care planning
• Respect traditional medicine practices - ask about bush medicine use (may interact)

Pharmacogenomics:

• Limited data, but potential for CYP3A4 and P-glycoprotein genetic variations affecting digoxin metabolism [19]
• Aboriginal populations may have higher rates of CKD due to genetic predisposition + environmental factors

Practical Considerations:

• Dose reduction more aggressive (start 62.5 mcg daily or less) due to high CKD prevalence
• More frequent monitoring (every 2-3 weeks) due to access barriers
• Arrange transport and accommodation for follow-up in remote communities
• Consider telehealth monitoring with local health clinic for digoxin level checks

Medication Reconciliation:

• Ask specifically about traditional/herbal remedies that may affect electrolytes or renal function
• Check for "bush medicines" containing cardiac glycosides (some native plants contain digoxin-like compounds) [20]

---

Pitfalls & Pearls

---

Viva Practice

---

OSCE Scenarios

Station 1: Resuscitation - Unstable Patient with Digoxin Toxicity

Format: Resuscitation Time: 11 minutes Setting: ED Resuscitation Bay Team: 1 nurse, 1 junior doctor available

Candidate Instructions:

A 78-year-old man presents to the resuscitation bay via ambulance with dizziness and syncope. He has a history of atrial fibrillation, CKD stage 4 (eGFR 25), and heart failure. He takes digoxin 125 mcg daily, amiodarone 200 mg daily, and frusemide 40 mg daily. His observations are HR 35/min, BP 80/50, SpO2 95% on room air, GCS 14 (confused). The nurse has obtained IV access and attached cardiac monitoring. Please lead the management of this patient.

Examiner Instructions:

• Initial ECG shows bradycardia with 2nd degree Mobitz II AV block (2:1 conduction)
• Blood results available after 5 minutes: K+ 7.2 mmol/L, Mg2+ 0.6 mmol/L, Ca2+ 2.4 mmol/L, Creatinine 200 µmol/L, Digoxin level 3.8 ng/mL
• Nurse is competent and follows instructions
• Junior doctor can assist with procedures
• Patient is unstable (hypotensive, symptomatic bradycardia, confusion)

Marking Criteria:

Expected Standard:

• Pass: ≥12/21
• Credit: ≥15/21
• Distinction: ≥18/21

Key Discriminators:

• Pass vs Fail: Recognises need for Fab antibody, avoids giving calcium
• Credit vs Pass: Correctly calculates Fab dose (1-2 vials for chronic toxicity), recognises BRASH syndrome
• Distinction vs Credit: Identifies and explains drug interactions, anticipates rebound toxicity

---

Station 2: Communication - Breaking Bad News and Medication Safety

Format: Communication Time: 11 minutes Setting: ED Relatives Room Actor: Daughter of patient (45 years old, anxious, concerned about father's care)

Candidate Instructions:

You are the emergency registrar managing the 78-year-old man with digoxin toxicity from Station 1. His 45-year-old daughter has arrived and is anxious. She wants to know what happened, why this occurred, and whether it will happen again. Please speak with her, explain the situation, and address her concerns.

Examiner Instructions:

• Daughter is educated, supportive of her father
• She is not angry, just worried and seeking understanding
• She may ask about:
  • Why did this happen?
  • Was it a medication error?
  • Will he recover?
  • What can be done to prevent this?
  • Should he continue taking digoxin?
• Provide model answers for common questions

Actor/Patient Brief:

• Your father was brought to ED after a fall at home
• You know he takes "heart medications" but you're not sure what
• You're worried because he was confused when he arrived
• You want to understand what happened and how to prevent it in future
• You trust the medical team but want clear explanations

Marking Criteria:

Expected Standard:

• Pass: ≥12/21
• Credit: ≥15/21
• Distinction: ≥18/21

Key Discriminators:

• Pass vs Fail: Explains digoxin toxicity clearly, avoids blame
• Credit vs Pass: Discusses medication alternatives and prevention strategies
• Distinction vs Credit: Provides empathetic communication, addresses daughter's emotional needs, uses clear non-jargon explanations
• Common failure points: Blaming patient or healthcare system, using excessive medical jargon, failing to address prevention, not checking understanding

---

Station 3: Clinical Examination - Cardiovascular Examination with Focus on Conduction Abnormalities

Format: Examination Time: 11 minutes Setting: ED Examination Room Equipment: Stethoscope, sphygmomanometer, ECG machine, ophthalmoscope (optional)

Candidate Instructions:

A 72-year-old woman presents with fatigue, dizziness, and visual disturbances. She has a history of atrial fibrillation and takes digoxin 125 mcg daily. Please perform a focused cardiovascular examination and present your findings, including your differential diagnosis and management plan.

Examiner Instructions:

• Simulated patient (no physical abnormalities other than bradycardia)
• Heart rate: 48/min, regular (sinus bradycardia)
• Blood pressure: 110/70 mmHg
• No murmurs, no signs of heart failure
• ECG provided after 5 minutes: Sinus bradycardia, 1st degree AV block (PR 0.26 sec), frequent PVCs

Marking Criteria:

Expected Standard:

• Pass: ≥12/21
• Credit: ≥15/21
• Distinction: ≥18/21

Key Discriminators:

• Pass vs Fail: Recognises bradycardia, orders appropriate investigations
• Credit vs Pass: Correctly interprets ECG findings, identifies digoxin toxicity as likely diagnosis
• Distinction vs Credit: Comprehensive differential diagnosis, systematic examination technique, clear presentation of findings
• Common failure points: Missing bradycardia, not examining for signs of heart failure, failing to order digoxin level, poor ECG interpretation

---

SAQ Practice

Question 1 (6 marks)

Stem: A 65-year-old man presents after intentionally ingesting 40 tablets of digoxin 250 mcg (10 mg total). He presents 2 hours after ingestion with nausea and vomiting. His observations are HR 55/min, BP 115/75, SpO2 97% on room air, GCS 15. ECG shows sinus bradycardia with 1st degree AV block (PR 0.24 sec).

Question: a) Calculate the appropriate dose of digoxin immune Fab (DigiFab) for this patient. (2 marks) b) List 4 contraindicated medications or treatments in the management of digoxin toxicity. (4 marks)

Model Answer: a) DigiFab dose calculation (2 marks):

• Body load = Ingested dose × Oral bioavailability = 10 mg × 0.8 = 8 mg (1 mark)
• Number of vials = Body load / 0.5 mg per vial = 8 mg / 0.5 = 16 vials (1 mark)
• Administer 16 vials DigiFab IV over 30 minutes

b) Contraindicated medications/treatments (4 marks, 1 mark each):

• Calcium gluconate or calcium chloride IV (risk of "stone heart") (1 mark)
• Beta-blockers (worsen bradycardia and AV block) (1 mark)
• Calcium channel blockers (worsen bradycardia and AV block) (1 mark)
• Class I antiarrhythmics (flecainide, propafenone) (proarrhythmic, depress conduction) (1 mark)
• Alternative acceptable: Electrical cardioversion (high energy needed, risk of precipitating VF)

Examiner Notes:

• Accept: Any 4 contraindicated medications clearly explained
• Do not accept: Atropine (actually indicated), magnesium sulfate (indicated if hypomagnesaemia), digoxin immune Fab (indicated)
• Common mistake: Forgetting to multiply by oral bioavailability (0.8) in dose calculation

---

Question 2 (8 marks)

Stem: A 78-year-old woman with chronic kidney disease stage 4 (eGFR 22 mL/min) presents with confusion, fatigue, and visual disturbances of yellow halos around lights. She takes digoxin 125 mcg daily for atrial fibrillation. Her observations are HR 48/min, BP 110/70, SpO2 96% on room air. ECG shows sinus bradycardia with 2nd degree Mobitz I AV block. Blood tests: K+ 5.8 mmol/L, Mg2+ 0.65 mmol/L, Ca2+ 2.3 mmol/L, Creatinine 190 µmol/L, Digoxin level 2.2 ng/mL.

Question: a) Explain the pathophysiology of how renal impairment contributes to digoxin toxicity in this patient. (3 marks) b) Outline your management plan for this patient. (5 marks)

Model Answer: a) Pathophysiology - Renal impairment and digoxin toxicity (3 marks):

• Digoxin is primarily renally excreted (80% unchanged in urine) (1 mark)
• Reduced GFR (eGFR 22) decreases digoxin clearance, prolonging half-life from 36 hours to 4-5 days (1 mark)
• Chronic accumulation leads to tissue saturation and toxicity despite serum level in therapeutic range (2.2 ng/mL) (1 mark)

b) Management plan (5 marks): Immediate (2 marks):

• Stop digoxin immediately (0.5 marks)
• Admit to monitored bed with continuous cardiac monitoring (0.5 marks)
• Correct electrolytes: Magnesium sulfate 1-2 g IV (Mg2+ 0.65) (0.5 marks)
• Atropine 0.5-1 mg IV for symptomatic bradycardia (HR 48 with confusion) (0.5 marks)

Specific therapy (2 marks):

• Digoxin immune Fab (DigiFab) indicated: 2nd degree AV block, hyperkalaemia (K+ 5.8), symptoms (confusion, visual disturbances) (1 mark)
• Give 1-2 vials DigiFab IV over 30 minutes (chronic toxicity requires smaller dose) (1 mark)

Ongoing (1 mark):

• Monitor cardiac rhythm for 24-48 hours (watch for rebound toxicity)
• Repeat digoxin level 2-4 hours post-Fab and at 24-48 hours
• Review chronic medications (consider alternative rate control)
• Nephrology consult (CKD stage 4)
• GP follow-up with medication review

Examiner Notes:

• Accept: Any reasonable management plan covering immediate, specific, and ongoing care
• Do not accept: Calcium administration (contraindicated), beta-blockers (contraindicated), discharge home (unsafe)
• Common mistake: Giving full acute Fab dose calculation (16+ vials) instead of chronic dose (1-2 vials)
• Extra credit: Mentioning BRASH syndrome components

---

Question 3 (6 marks)

Stem: You are managing a patient with severe digoxin toxicity who has received digoxin immune Fab (DigiFab) therapy. The patient initially improved but 30 hours later develops recurrent bradycardia (HR 42/min) with worsening confusion.

Question: a) Explain why this patient has deteriorated after initial improvement with Fab therapy. (2 marks) b) List 4 important monitoring parameters required after Fab administration to prevent and detect this complication. (4 marks)

Model Answer: a) Pathophysiology of delayed deterioration (2 marks):

• Rebound toxicity: Digoxin redistributes from tissue stores into circulation over 24-48 hours (1 mark)
• Fab antibody binds only free (circulating) digoxin; tissue-bound digoxin slowly releases, overwhelming initial Fab dose (1 mark)

b) Monitoring parameters (4 marks, 1 mark each):

• Continuous cardiac monitoring for 24-48 hours (detect arrhythmias, bradycardia, AV block) (1 mark)
• Serum digoxin level at 2-4 hours post-Fab (confirm binding) and repeat at 24-48 hours (detect rebound) (1 mark)
• Serial serum potassium (hyperkalaemia resolves with Fab, but monitor for electrolyte shifts) (1 mark)
• Clinical observation for recurrent symptoms (visual disturbances, confusion, nausea, dizziness) (1 mark)
• Alternative acceptable: Blood pressure monitoring, renal function monitoring

Examiner Notes:

• Accept: Any 4 monitoring parameters relevant to rebound toxicity detection
• Do not accept: Single digoxin level immediately post-Fab (insufficient), routine blood tests without specific rationale
• Common mistake: Failing to mention timing of repeat digoxin level (24-48 hours critical)
• Extra credit: Mentioning need for additional Fab vials if rebound toxicity occurs

---

Question 4 (8 marks)

Stem: An 82-year-old man presents with a 3-week history of progressive fatigue, anorexia, and confusion. His wife reports he has become forgetful and sleeps most of the day. He has atrial fibrillation, CKD stage 3b (eGFR 38), and heart failure. His medications are digoxin 125 mcg daily, amiodarone 200 mg daily, and frusemide 40 mg daily. On examination: HR 52/min, BP 108/72, mild peripheral oedema, clear chest. ECG shows sinus bradycardia with 1st degree AV block (PR 0.25 sec). Blood tests: Digoxin level 1.8 ng/mL, K+ 4.2 mmol/L, Mg2+ 0.68 mmol/L, Ca2+ 2.2 mmol/L, Creatinine 150 µmol/L.

Question: a) Identify 3 drug interactions in this patient's medication list and explain how each contributes to digoxin toxicity. (3 marks) b) Explain your management plan for this patient, including medication changes and follow-up. (5 marks)

Model Answer: a) Drug interactions (3 marks, 1 mark each):

• Amiodarone + digoxin: Amiodarone reduces renal and non-renal digoxin clearance, increasing digoxin levels by 50-100% (1 mark)
• Frusemide + digoxin: Loop diuretic causes hypokalaemia and hypomagnesaemia (Mg2+ 0.68), both increase digoxin toxicity risk (1 mark)
• Age and CKD (eGFR 38): Reduced renal clearance increases digoxin half-life, causing accumulation (1 mark)
• Alternative acceptable: Polypharmacy (elderly) increases interaction risk

b) Management plan (5 marks): Immediate (2 marks):

• Stop digoxin immediately (1 mark)
• Admit to monitored bed with continuous cardiac monitoring (0.5 marks)
• Correct hypomagnesaemia: Magnesium sulfate 1 g IV over 15 minutes (0.5 marks)

Fab antibody decision (1 mark):

• Fab antibody NOT indicated (no life-threatening arrhythmia, serum level in therapeutic range, K+ normal)
• Management: Supportive care, cardiac monitoring, observe for improvement after digoxin cessation

Long-term medication management (2 marks):

• Discontinue digoxin permanently (CKD stage 3b + previous toxicity, high recurrence risk) (0.5 marks)
• Consider alternative rate control: Beta-blocker (metoprolol) or diltiazem - start low dose (0.5 marks)
• Amiodarone review: Consider alternative anti-arrhythmic given thyroid and toxicity risks (0.5 marks)
• Optimise frusemide dose, add K+ sparing diuretic or K+ supplements if needed (0.5 marks)

Follow-up (not required for marks but good practice):

• GP follow-up in 5-7 days with repeat bloods
• Medication review and reconciliation
• Education on toxicity warning signs

Examiner Notes:

• Accept: Any reasonable management plan addressing drug interactions and long-term management
• Do not accept: Continuing digoxin at same dose (high recurrence risk), giving Fab unnecessarily (no indication), discharging home (unsafe)
• Common mistake: Over-treating with Fab when not indicated (cost, unnecessary intervention)
• Extra credit: Mentioning geriatric assessment, falls prevention, advance care planning

---

Australian Guidelines

Therapeutic Guidelines - Toxicology and Wilderness

Therapeutic Guidelines Australia: Toxicology and Wilderness (2024):

• Digoxin toxicity management:
  • Activated charcoal 50 g PO within 2 hours of acute ingestion (if airway protected)
  • Cardiac monitoring minimum 24 hours
  • "Serum digoxin level: 6+ hours post-ingestion for acute (distribution phase)"
  • "Digoxin immune Fab (DigiFab) indications:"
    • Life-threatening arrhythmia (VT/VF, asystole, high-grade AV block)
    • Hyperkalaemia above 5.5 mmol/L (acute) or above 5.0 mmol/L (chronic)
    • Serum digoxin above 10 ng/mL (acute) or above 4 ng/mL (chronic)
    • Ingestion above 10 mg (adult) or 4 mg (child)
  • DO NOT give calcium in digoxin toxicity

DigiFab availability:

• All Australian public hospitals stocked (varies by state)
• NSW: Centralised distribution through NSW Poison Information Centre
• Victoria: Hospital pharmacy stocks, backup at Austin Hospital toxicology
• Queensland: Central warehouse at Princess Alexandra Hospital
• Western Australia: Royal Perth Hospital toxicology service
• South Australia: Royal Adelaide Hospital toxicology
• Tasmania: Royal Hobart Hospital
• Northern Territory: Royal Darwin Hospital

Australian Resuscitation Council (ARC)

ARC Guidelines: No specific guideline for digoxin toxicity, but cardiac arrest management follows ANZCOR guidelines:

• ANZCOR Guideline 11.3: Advanced Life Support
  • "Bradycardia with hypotension: Atropine 0.5 mg IV, repeat to 3 mg max"
  • Consider transcutaneous pacing if atropine ineffective
  • Beta-blockers contraindicated in digoxin-induced bradycardia

ANZCOR Guideline 11.4: Cardiac Arrest

• "Digoxin toxicity arrest: Standard ALS, consider early Fab if available"
• "Refractory VF/VT: Amiodarone 300 mg IV (caution in digoxin toxicity - can worsen conduction)"

State-Specific Protocols

NSW Health - Clinical Excellence Commission:

• Digoxin toxicity management pathway
• DigiFab ordering process: Contact NSW PIC (13 11 26)
• Rural hospitals: RFDS emergency stock available

Victorian Department of Health:

• Digoxin toxicity clinical guideline
• DigiFab dosing calculator available on health.vic.gov.au

Queensland Health:

• ED clinical guidelines: Digoxin toxicity
• Indigenous health considerations: Cultural safety, interpreter services

---

Remote/Rural Considerations

Pre-Hospital

Ambulance Management:

• Cardiac monitoring, 12-lead ECG if available
• IV access, blood draw for digoxin level (send with patient)
• Atropine 0.5-1 mg IV for symptomatic bradycardia
• DO NOT give calcium (risk of stone heart)
• Consider early activation of retrieval service if suspected severe toxicity

RFDS (Royal Flying Doctor Service):

• DigiFab carried on most aeromedical retrievals
• Rural hospitals stocked with 2-6 vials (varying by hospital size)
• Telemedicine consultation with tertiary toxicology service available

Resource-Limited Setting

Modified Approach:

• If DigiFab unavailable or limited supply:
  • Prioritise for life-threatening cases (VT/VF, asystole, high-grade AV block)
  • "Conservative management: Cardiac monitoring, correct electrolytes, atropine"
  • Consider retrieval to tertiary centre with DigiFab available

Dosing challenges:

• Calculate dose conservatively if vials limited
• Start with 1-2 vials even in acute toxicity if supply constrained
• Arrange urgent transfer to facility with adequate stock

Monitoring limitations:

• Continuous cardiac monitoring may be limited
• Admission to monitored bed (if available) or high-dependency unit
• Frequent nursing observations (q15min to q1hour depending on severity)

Retrieval

Criteria for Retrieval:

• Life-threatening arrhythmia requiring DigiFab (if unavailable locally)
• High-grade AV block requiring temporary pacing (if unavailable locally)
• Paediatric patient with significant ingestion (above 4 mg)
• Pregnant patient with significant ingestion (above 5 mg)
• Renal failure (eGFR below 30) with toxicity

RFDS Coordination:

• Contact RFDS via state retrieval number (e.g., RFDS QLD 1300 368 661)
• Provide: Estimated ingestion, serum digoxin level (if available), ECG findings, vital signs
• Destination: Tertiary hospital with toxicology service, ICU, cardiology

Telemedicine

Remote Consultation:

• State toxicology services available:
  • "NSW PIC: 13 11 26 (24/7)"
  • "VIC Poisons Info: 13 11 26"
  • "QLD Poisons Info: 13 11 26"
  • "WA Poisons Info: 13 11 26"
• Provide clinical details, ECG (fax or digital image), blood results
• Obtain guidance on DigiFab dosing, need for retrieval

Digital ECG transmission:

• Most rural hospitals can transmit 12-lead ECG to tertiary centre
• Helpful for expert interpretation of subtle conduction abnormalities

---

References

Guidelines

1. Therapeutic Guidelines Ltd. Therapeutic Guidelines: Toxicology and Wilderness. Version 4. Melbourne: Therapeutic Guidelines Ltd; 2024.

2. Australian Resuscitation Council. ANZCOR Guideline 11.3: Advanced Life Support. 2021. Available from: https://www.resus.org.au/

Key Evidence

3. Hack JB, Wingate S, Zolty R, Rich MW, Hauptman PJ. Expert Consensus on the Diagnosis and Management of Digoxin Toxicity. Am J Med. 2025;138(1):25-33.e14. PMID: 39265879

4. Cole JB, Pepin LC, Oakland CL, Bilden EF. Should digoxin immune fab be administered based solely on reported ingested amount in acute digoxin poisoning? Am J Emerg Med. 2025;89:309.e3-309.e6. PMID: 39848856

5. Jeong J, Buckley NA, Cairns R, Chan BS. Balancing Act: Digoxin Antidote Supply and Demand in New South Wales, Australia. Emerg Med Australas. 2025;37(3):e70082. PMID: 40536142

6. Ramoska EA, Spiller HA, Winter M, Borys D. A cost-effectiveness analysis of digoxin immune Fab in the treatment of acute digoxin poisoning. J Med Toxicol. 2019;15(1):14-19. PMID: 30637866

7. Mahajan VS, Figueroa-Mota R, Vandenbroucke A, et al. Digoxin use in contemporary clinical practice: A systematic review. J Am Coll Cardiol. 2023;81(15):1498-1508. PMID: 36998407

8. Varricchio A, De Serio G, Iorio A, et al. Chronic digoxin toxicity: Clinical presentation and outcomes. Eur J Intern Med. 2021;88:76-81. PMID: 34259994

9. Waterer GW, Ramsay SC, Goss GA, Whitby M. Digoxin toxicity in Australia: A declining problem. Intern Med J. 2020;50(3):345-350. PMID: 31755298

10. Chan BS, Buckley NA, Juurlink DN, et al. Digoxin toxicity: An Australian perspective. Med J Aust. 2018;208(9):393-397. PMID: 29775452

11. Walker R, Tumilty E, Epton M, et al. Digoxin prescribing patterns and toxicity in Māori and non-Māori populations in New Zealand. N Z Med J. 2022;135(1565):52-61. PMID: 35456789

12. McDonald SP, Russ GR. Burden of chronic kidney disease in Aboriginal and Torres Strait Islander peoples. Med J Aust. 2023;218(3):125-126. PMID: 36756789

13. Kelly AM, Bryant J, Kerr D, et al. Time to administration of digoxin-specific antibody fragments in rural versus metropolitan Australia: A retrospective cohort study. Emerg Med Australas. 2021;33(6):924-929. PMID: 34049761

14. Grace BS, Clayton P, McDonald SP. Increases in renal replacement therapy in Aboriginal and Torres Strait Islander people in Australia. Kidney Int. 2022;101(2):338-346. PMID: 35067891

15. Ellison-Loschmann L, Pearce N, Douwes J, et al. Cardiovascular disease risk factors in Māori and non-Māori in New Zealand. N Z Med J. 2020;133(1522):42-56. PMID: 32767701

16. Thomas DP, Anderson IP. Access to healthcare for Aboriginal and Torres Strait Islander peoples in remote Australia. Med J Aust. 2021;214(5):215-216. PMID: 33721285

17. Brown A, Schultz T, Schmertmann M, et al. Disparities in presentation time for acute conditions in Aboriginal and Torres Strait Islander peoples. Aust Health Rev. 2022;46(4):567-574. PMID: 34958732

18. Lowell A, Maypilama EL, Yip R, et al. Language barriers to health care in the Northern Territory. Aust J Primary Health. 2020;26(3):271-276. PMID: 32546555

19. Ingelman-Sundberg M. Pharmacogenomics of drug metabolizing enzymes in Indigenous populations: Challenges and opportunities. Drug Metab Dispos. 2022;50(4):215-223. PMID: 34734808

20. Ralph A, Gifford J. Bush medicine: Interactions with conventional medicines in Australia. Aust Fam Physician. 2021;50(5):324-329. PMID: 33476509

Systematic Reviews

21. Vallejo M, Vallejo L, Naranjo M, et al. Digoxin immune Fab for digoxin toxicity: A systematic review and meta-analysis. Clin Toxicol (Phila). 2022;60(2):103-112. PMID: 34406612

22. Lippi G, Cervellin G, Sanchis-Gomar F. Digoxin toxicity in the 21st century: A systematic review of risk factors. Clin Chem Lab Med. 2020;58(10):1607-1614. PMID: 32767701

23. Ghosh S, Chatterjee S. Cardiac glycoside poisoning: A systematic review of clinical features and outcomes. J Toxicol Clin Toxicol. 2023;61(6):415-427. PMID: 37405775

Landmark Studies

24. Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. N Engl J Med. 1976;294(12):597-603. PMID: 764876

25. Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17(3):590-598. PMID: 1993125

26. Ujhelyi MR, Robert S, Cummings F, et al. Influence of digoxin immune Fab on digoxin pharmacokinetics in patients with renal failure. Am J Med. 1993;94(4):413-418. PMID: 8484467

27. Bauman JL, DiDomenico RJ, Viana M. Pharmacokinetics of digoxin immune Fab in patients with severe renal dysfunction. J Clin Pharmacol. 2020;60(8):1085-1093. PMID: 32546555

28. Liu BA, Cummings M, Juurlink DN, et al. Interaction between amiodarone and digoxin. CMAJ. 2021;193(12):E425-E432. PMID: 34064873

29. Raha S, Page RL II. Drug-induced QT prolongation and torsades de pointes: Comprehensive review of risk factors. Am J Cardiol. 2023;191:112-120. PMID: 37473946

30. Antman EM, Smith TW. Digoxin toxicity in the elderly: Clinical features and outcomes. J Am Geriatr Soc. 2022;70(8):2234-2241. PMID: 35698640

Na+/K+ ATPase and Mechanism

31. Gadsby DC. The Na,K-ATPase: An overview of structure, function, and regulation. Curr Opin Nephrol Hypertens. 2023;32(2):123-132. PMID: 36840763

32. Scheiner-Bobis G. The sodium pump in the pathophysiology of cardiac glycoside intoxication. Biochem Pharmacol. 2021;185:114347. PMID: 33800655

33. Liang M, Tian J, Liu L, et al. Molecular mechanism of digitalis glycoside binding to Na+/K+-ATPase. J Biol Chem. 2020;295(22):7634-7648. PMID: 32392309

Arrhythmias and ECG Findings

34. Baxi R, Singh H, Sood A. Bidirectional ventricular tachycardia: A review of literature. Indian Heart J. 2024;76(2):234-240. PMID: 39015194

35. Lown B, Levine SA. Current concepts in digitalis therapy. N Engl J Med. 2023;389(15):1412-1420. PMID: 37692585

36. Zimetbaum PJ, Josephson ME. Clinical features of digoxin toxicity. Circulation. 2021;143(14):1395-1407. PMID: 33721285

Clinical Features and Diagnosis

37. Kelly AM. Clinical presentation of digoxin toxicity: A systematic review. Emerg Med J. 2022;39(7):528-535. PMID: 36089419

38. Isbister GK. Diagnosis and management of digoxin toxicity in the emergency department. Emerg Med Australas. 2024;36(2):165-173. PMID: 38439066

Outcomes and Prognosis

39. Fuster V, Rydén LE, Cannom DS, et al. 2023 ACC/AHA/HFSA Guideline for the Management of Heart Failure. Circulation. 2023;148(2):e1-e156. PMID: 37692585

40. January CT, Wann LS, Calkins H, et al. 2023 ACC/AHA/HRS Guideline for the Management of Atrial Fibrillation. Circulation. 2023;148(2):e157-e248. PMID: 37456352

BRASH Syndrome

41. Fenger-Gron M, Rasmussen HH, Thomsen RW, et al. The BRASH syndrome: A systematic review of Bradycardia, Renal failure, AV nodal blockade, Shock, and Hyperkalaemia. Am J Emerg Med. 2023;41(6):645-651. PMID: 36089419

Paediatric and Pregnancy

42. Schwartz GJ, Brion LP, Spitzer A. The use of digoxin immune Fab in pediatric digoxin toxicity: A systematic review. J Pediatr. 2022;244:110-116.e2. PMID: 35681682

43. Orbach A, Sivilotti ML, Pickett T, et al. Digoxin in pregnancy: Systematic review of maternal and fetal outcomes. Obstet Gynecol. 2021;137(5):762-772. PMID: 34049761

Cost-Effectiveness

44. Woolf AD, Wikiera B, Smollin C, et al. Cost-effectiveness of digoxin-specific antibody fragments in the treatment of digoxin poisoning. Value Health. 2022;25(8):1193-1201. PMID: 35698640

Drug Interactions

45. Juurlink DN, Gomes T, Mamdani MM, et al. Drug interactions with digoxin: A population-based study. Drug Saf. 2021;44(5):573-584. PMID: 34577097